Medipost (CEO Yang Yoon-sun양윤선) has obtained a patent in the United Kingdom for its stem cell-based Alzheimer’s treatment composition, the company announced Wednesday.
The patent’s title is “Composition comprising mesenchymal stem cells or culture solution of mesenchymal stem cells for the prevention or treatment of neural diseases.” Particularly the latest patent is about pharmaceutical composition, which includes cord blood-derived mesenchymal stem cell that secretes the GDF-15 protein, and its culture solution.
Medipost has recently won a patent in the United Kingdom with technology to treat Alzheimer’s disease using stem cells. (Source: Medipost website)
"We are applying this patented technology to develop ‘neurostem’ for the treatment of Alzheimer's disease, and are having Phase I and II clinical trials under way," a Medipost official said. "The patent technology applies to various neurological diseases such as Parkinson's disease, depression, epilepsy, and multiple sclerosis."
Medipost has acquired similar patents in other countries, including Korea, Singapore, Australia, Mexico, and Japan. The company now has 30 patents in the fields of brain and nervous systems alone, such as dementia and brain tumors, with this patent acquisition, the company said.
<© Korea Biomedical Review, All rights reserved.>